Silence Therapeutics plc (SLN)

Silence Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	25.38	17.5	12.42	5.48	0.24
Revenue Growth (YoY)	44.99%	40.97%	126.59%	2145.49%	-
Cost of Revenue	10.32	10.88	7.46	3.76	0
Gross Profit	15.06	6.62	4.96	1.72	0.24
Selling, General & Admin	20.64	19.61	20.01	13.98	9.64
Research & Development	44.03	35.61	30.77	20.21	13.34
Other Operating Expenses	0	0	0	3.37	0
Operating Expenses	64.66	55.21	50.77	37.56	22.98
Operating Income	-49.6	-48.59	-45.81	-35.85	-22.73
Interest Expense / Income	2.15	0.05	0.05	0.32	0.16
Other Expense / Income	-1.45	-1.27	-0.01	-0.13	-0.03
Pretax Income	-50.31	-47.37	-45.86	-36.04	-22.87
Income Tax	-7.04	-6.88	-6.45	-3.49	-3.29
Net Income	-43.27	-40.49	-39.41	-32.55	-19.58
Shares Outstanding (Basic)	116	108	90	78	78
Shares Change	7.74%	19.94%	14.55%	-	-
EPS (Basic)	-	-	-	-	-0.78
EPS (Diluted)	-	-	-	-	-0.78
Free Cash Flow	-39.4	-45.6	5.5	-11.28	1.72
Free Cash Flow Per Share	-1.02	-1.27	0.18	-0.43	0.07
Gross Margin	59.34%	37.83%	39.94%	31.34%	100.00%
Operating Margin	-195.48%	-277.66%	-369.02%	-654.26%	-9317.21%
Profit Margin	-170.51%	-231.35%	-317.44%	-594.03%	-8025.41%
Free Cash Flow Margin	-155.25%	-260.53%	44.26%	-205.95%	704.10%
EBITDA	-47.7	-46.84	-45.39	-35.24	-22.26
EBITDA Margin	-187.96%	-267.66%	-365.63%	-643.22%	-9120.90%
Depreciation & Amortization	0.46	0.48	0.41	0.48	0.45
EBIT	-48.16	-47.32	-45.8	-35.72	-22.71
EBIT Margin	-189.79%	-270.39%	-368.94%	-651.91%	-9306.15%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).